I would have to agree with you Aladdin. There is no doubt capital is needed and there currently appear to be very few options other than dilution which at this depressed sp would be a disaster. There's nothing the company has that's "mature" enough that would attract a partner so that's not a viable option.
This goes back to what we've been saying for quite some time now. Adams has kicked this can down the road for so long and now he's gonna kick the "cans" of his stockholders with another (most likely terribly dilutive) cap raise.
The pace this company moves at (especially with biosynthesis) is becoming comical. They clearly haven't overcome the biological burden yet so there's no way they are even close to providing cost models or commercializing scale up. I know on the call they said again that they hope to decide within the next "few weeks", however IMHO, I doubt we get any answer by the next quarterly call.
And by the way, I was less than thrilled with the "accounting error" they reported. Any 3rd year accounting/finance major at any university would've caught that mistake. Mr. Colwill has been with the company for about 6 months and already pulled such a boneheaded mistake? I thought this guy was supposed to be the greatest?! At least according to all the pumpers...Ugh...
News 
Market Data 
Discover 
